Loading
Life sciences · Journal article
Future Oncology · October 1, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Plain Language SummaryWhat is this summary about?In advanced small cell lung cancer, radiation therapy or surgery cannot eradicate the cancer because the cancer has spread widely. Therefore, this cancer is treated by combining immunotherapy drugs (drugs that stimulate a person’s own immunity to attack cancer cells) and chemotherapy drugs (drugs that directly attack cancer cells). Atezolizumab is a type of immunotherapy drug.The IMpower133 study compared the efficacy (how well a study drug works) and safety of atezolizumab in combination with the chemotherapy drugs carboplatin and etoposide for the treatment of advanced small cell lung cancer compared with chemotherapy alone.To participate in this trial, it was necessary to meet certain criteria, which are described below. However, it was thought that there were many patients who did not meet these criteria in daily practice in Japan. Therefore, the J-TAIL-2 study investigated the efficacy and safety of atezolizumab and chemotherapy combination therapy in routine medical care in Japan by relaxing the conditions for participation in the study and including patients who were considered unable to participate in the IMpower133 study. This study did not directly compare these patients with a ‘control group’ receiving different treatments. This article presents the results of the J-TAIL-2 study, which was published in JTO Clinical and Research Reports in 2024.What are the key takeways?The J-TAIL-2 study included 403 patients from medical institutions in Japan. Approximately 70% of the patients who participated in this study spent more than half of the day in bed or chair, had fibrosis in the lungs (a condition in which the walls of the lungs are damaged and become hard and thick, making it difficult to breathe); had cancer that had spread to the brain and caused symptoms such as headaches, impaired consciousness, and cognitive decline; and had autoimmune diseases in addition to lung cancer. A patient who had any of these characteristics was not eligible for the IMpower133 study.The study revealed that the efficacy of atezolizumab and chemotherapy in combination therapy in daily practice in Japan was similar to the results of the IMpower133 study.In addition, safety across participants in the J-TAIL-2 study was manageable, with no reported side effects that had not been identified in the past.What were the main conclusions reported by the researchers?These results suggest that this combination therapy may be useful in daily practice, including for patients with poor health. These results are consistent with the results of the IMpower133 study.Clinical trial number: https://center6.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000047121